Navigation Links
Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics

CAMBRIDGE, England, December 21, 2011 /PRNewswire/ --

Arecor Limited has entered into a collaboration agreement with Eli Lilly and Company to assess Arecor's advanced protein formulation technologies for possible use with Lilly's growing pipeline of biological-based drugs.  Under this agreement, Arecor will develop stable aqueous or higher concentration formulations of emerging protein and peptide drug candidates developed by Lilly.  In addition, Arecor will work with Lilly to potentially offer improved formulations of Lilly's existing therapeutic proteins in several therapeutic areas.  

Tom Saylor, CEO of Arecor, stated, "The next generation of protein and peptide therapeutics present significant formulation challenges. Arecor's stabilization tools may enable new products and presentations, which would otherwise not be possible, without additional processing or changes to standard manufacturing practices.  Lilly's strong support of innovation and emerging technologies offers Arecor the potential to apply Arecor's broad-ranging expertise in biomolecule stabilization to a leader in pharmaceutical application of the next generation of biologics."

Arecor is a pioneer in the stabilization of biologic molecules, a key challenge in the development of many therapeutic proteins, vaccines and diagnostics. Arecor Limited was established to provide formulation solutions to pharmaceutical and biotech companies developing proteins, vaccines and diagnostics based upon new insights into interactions between proteins and their immediate environment. Proteins and vaccines are often fragile entities, and stability can represent significant constraints in the development of new products and extending the use of existing products. Arecor has developed Arestat™, a patented set of tools for stabilization which address the main pathways of degradation. As a simple reformulation, Arestat™ can be readily incorporated into standard manufacturing practice, without covalent modification of the biologic and using excipients approved for the route of delivery. Arecor currently has active feasibility programs and licenses with many of the top pharmaceutical and biotech companies on a wide range of proteins and vaccines.


Tom Saylor, CEO
Arecor Limited
2 Cambridge Science Park
Cambridge, UK

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuse Science Announces the Launch of its Analgesic and Diabetic Oral Fuse Delivery (OFD) Research Project Platforms
2. Enlight Biosciences Forms New Partnerships with AstraZeneca and Novo Nordisk
3. Diablo Valley Oncology Performs Breast Intraoperative Radiation Procedure - First in the East Bay
4. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
5. ArjoHuntleigh Forms New Division to Enhance the Quality Home Medical Care
6. Digital ArtForms Debuts iMedic3D, a Radically Different Approach to Radiology, at RSNA ‘11, and Announces the Addition of Dr. Eliot Siegel and Dr. David Kim to Its Advisory Board Members
7. Awarepoint Corporation and MEDITECH Collaborate to Integrate Technology Platforms
8. Mindray Introduces Enhancements for M Series Ultrasound Platforms at ASA
9. ContinuumRx Forms Healthcare Joint Venture with Mississippi Baptist Health Systems
10. Stereotaxis Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms
11. Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms
Post Your Comments:
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... DUBLIN , Nov. 27, 2015 Research ... of the "Global Intrauterine Devices Market 2015-2019" ... --> In this report, the author ... intrauterine devices market for 2015-2019. To calculate the market ... of following type of products: Hormonal IUDs and copper ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... ... The print component of “Supporting Our Caregivers” is distributed ... Minneapolis, South Florida, with a circulation of approximately 250,000 copies and an estimated ... media strategy and across a network of top news sites and partner media ...
(Date:11/27/2015)... ... 27, 2015 , ... Consistent with the Radiology Business ... Better Radiology Marketing Programs meeting will showcase some of the best 2015 ... Caesars Palace in Las Vegas with a pre-conference session on a collaborative approach ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... prided itself for not only fulfilling the needs of advisers and clients but ... affordable price and providing top-tier customer service. However, there's always room for improvement, ...
(Date:11/27/2015)... Chicago, IL (PRWEB) , ... November 27, 2015 ... ... some of the largest, most successful and prominent nonprofit healthcare organizations in the ... and governance involvement with various organizations, and helped advance the healthcare industry as ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
Breaking Medicine News(10 mins):